Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neuroendocrine Tumors: early-phase trial registry
27 of 53 indexed Neuroendocrine Tumors trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #265 of 28,707 conditions by registered trial count.
53 US clinical trials · 27 currently recruiting · #265 of 28,707 conditions by registered trial count
Neuroendocrine Tumors: 53 US clinical trials tracked, 27 recruiting.
Neuroendocrine Tumors is the subject of 53 registered US clinical trials on ClinicalTrials.gov, 27 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 40 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 6 of these trials.
Enrollment posture brief
Registry condition neuroendocrine-tumors
OPEN 27 | RECR 51% | LATE 3 | EARLY 40 | RANK #265 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Chronic Pancreatitis (51% recruiting · 43 trials)
Neuroendocrine Tumors lists 27 open slots (51% of 53 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neuroendocrine Tumors on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neuroendocrine Tumors is recruiting above its size-band peers.
27 of 53 indexed trials (50.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Neuroendocrine Tumors trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 6 of 53 trials (11.3%). 39 distinct sponsors appear on at least one study for this condition label.
-
Typical Neuroendocrine Tumors enrolment sits around 68 participants.
Median target enrolment is 68 among the 53 trials that report a genuine target (sentinel values excluded). 31 of those (58.5%) plan for fewer than 100 participants.
-
Neuroendocrine Tumors research is mostly interventional.
47 interventional and 6 observational studies make up this index (88.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
53 total, page 1 of 2
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)
NCT04074135
Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
National Cancer Institute (NCI)
NCT05237934
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RayzeBio
NCT05477576
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Cancer Institute (NCI)
NCT03412877
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Udai Kammula
NCT03935893
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Circle Pharma
NCT06577987
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Case Comprehensive Cancer Center
NCT06263088
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Crinetics Pharmaceuticals
NCT07129252
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Chimeric Therapeutics
NCT06055439
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
National Cancer Institute (NCI)
NCT03206060
Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
Barbara Ann Karmanos Cancer Institute
NCT06908629
177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry
University of Iowa
NCT06395402
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Fox Chase Cancer Center
NCT05263050
The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)
University of Utah
NCT07151391
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
National Cancer Institute (NCI)
NCT06041516
CapTemY90 for Grade 2/3 NET Liver Metastases
Abramson Cancer Center at Penn Medicine
NCT04339036
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility
NCT06805825
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
National Cancer Institute (NCI)
NCT04086485
Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
Methodist Health System
NCT04090034
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
Peter Hosein, MD
NCT06889493
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
University of California, San Francisco
NCT05746208
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Teclison
NCT02174549
F-Tryptophan PET/CT in Human Cancers
Barbara Ann Karmanos Cancer Institute
NCT05556473
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
Aadi Bioscience
NCT05997056
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Anusha Kalbasi
NCT04119024
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
University of Wisconsin, Madison
NCT06122610
177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
Molecular Targeting Technologies
NCT05475210
Neuroendocrine Tumors - Patient Reported Outcomes
University of Iowa
NCT05064150
Post-Authorization Long-Term Safety Study of LUTATHERA
Advanced Accelerator Applications
NCT03691064
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Hoffmann-La Roche
NCT02568267
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
ITM Solucin
NCT03049189
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
ITM Solucin
NCT04919226
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
23andMe
NCT05199272
Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients
Orano Med
NCT05153772
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Dwight Owen
NCT03728361
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
University of Michigan Rogel Cancer Center
NCT04848337
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors
Yusuf Menda
NCT03335670
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
David Bushnell
NCT06148636
Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery
Abramson Cancer Center at Penn Medicine
NCT06204159
Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
NCT06448208
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
Memorial Sloan Kettering Cancer Center
NCT04544098
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Providence Health & Services
NCT05249114
EchoTip AcuCore Post-Market Clinical Study
Cook Research Incorporated
NCT06358001
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
Sue O'Dorisio
NCT02441062
Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
Jonsson Comprehensive Cancer Center
NCT01873248
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
Arbutus Biopharma Corporation
NCT01262235
Dual-Tracer Theranostic PET
University of Utah
NCT05680675
18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies
Memorial Sloan Kettering Cancer Center
NCT02348749
Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors
Dana-Farber Cancer Institute
NCT00137774
Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
Cylene Pharmaceuticals
NCT00780663
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 21 |
| Phase 2 | 19 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Neuroendocrine Tumors records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neuroendocrine Tumors trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neuroendocrine Tumors page
53 registered trials, 27 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 27 Neuroendocrine Tumors trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Neuroendocrine Tumors trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neuroendocrine Tumors condition card totals 53 registered trials; most-linked intervention Everolimus; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.